Sarah Sammons

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Sarah Sammons
Jun 20, 2025, 11:05 | Career
Elizabeth Mittendorf Will Join BIDMC as Chief of the Division of Breast Surgery
BIDMC - Beth Israel Deaconess Medical Center shared  a post on X: "We’re proud to…
Jun 16, 2025, 11:04 | Blog
Sarah Sammons: How Cancer Cells Travel to New Tissues and Take Hold
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, posted on…
Jun 3, 2025, 16:58 | Insight
Paolo Tarantino Presented DATO-Base Trial Poster at ASCO 2025 on Breast Cancer CNS Metastases
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared on…
Jun 3, 2025, 13:23 | Insight
Sarah Sammons: RLY2608 and Fulvestrant in HR+/HER2- PIK3CA mutant breast cancer
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared on…
Jun 1, 2025, 16:25 | Blog
Sarah Sammons: 50% of patients do not make it to second line therapy in mTNBC
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared on…
Jun 1, 2025, 12:10 | Blog
Luca Arecco: Sac-TMT Shows Promising Efficacy in Advanced TNBC as 1st-Line Therapy
Luca Arecco, Clinical Research Fellow at ESMO, posted on X: "Rapid oral mBC  OptiTROP-Breast05: Sac-TMT…
May 31, 2025, 13:44 | Blog
Sarah Sammons Highlights 77% Response Rate with Carboplatin, Bevacizumab, and PD-1 Inhibitors in TNBC Brain Metastases
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a…
May 27, 2025, 10:32 | Blog
Sarah Sammons: Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn: "Join me…
May 20, 2025, 15:05 | Insight
New JCO Oncology Practice Piece on Debunking Myths of Hope in Cancer Care
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post by Ramy…
May 19, 2025, 09:44 | Blog
Sarah Sammons Raises Concerns Over Cut to Nurses Health Study II
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, posted on X: "Almost every…
May 10, 2025, 21:51 | Blog
Join Dana-Farber’s Breast Oncology Center for a day of finding balance through wellness, education and community
Dana-Farber’s Breast Oncology Center shared a post on X: "Join us in person at Dana-Farber…
May 9, 2025, 10:15 | Blog
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X…
May 5, 2025, 10:37 | Blog
Amol Akhade Launches Clinician Poll on Adjuvant Therapy for Breast Cancer
Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared…
Apr 29, 2025, 17:22 | Blog
Sarah Sammons: Infinite Strength supports single mothers with advanced breast cancer
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on LinkedIn:…
Apr 13, 2025, 02:37 | Opinion
Sarah Sammons: Ting Bao's discussion about "Integrative Medicine in Metastatic Breast Cancer"
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X:…
Apr 12, 2025, 19:25 | Blog
Sarah Sammons: Lavender essential oils can help with scan related anxiety
Sarah Sammons, Breast Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X:…
Mar 31, 2025, 08:53 | Blog
Sarah Sammons: A few highlights from my ADC resistance talk at LACOG-GBECAM 2025
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn: "A few highlights…
Feb 4, 2025, 09:30 | Blog
Sarah Sammons: Finally brain MRI screening data in MBC
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X: "Finally…
Jan 23, 2025, 14:32 | Blog
Exciting progress in metastatic breast cancer research - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared the following on X: “Exciting progress in Metastatic Breast Cancer…
Jan 20, 2025, 13:55 | Blog
Sarah Sammons: US women have a cancer problem that is getting worse
Sarah Sammons, Medical oncologist at Dana-Farber’s Breast Oncology Center, posted on X: "US women have…
Jan 19, 2025, 07:17 | Science
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer
Dana-Farber’s Breast Oncology Center posted on X, about recent paper by Kevin Kalinsky et al.,…
Jan 5, 2025, 16:03 | Science
Yakup Ergün: Metronomic Capecitabine Plus AI as Initial Therapy in HR+/HER2- mBC by Ruo-Xi Hong et al.
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Dec 26, 2024, 15:50 | Insight
Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: “Here’s the most recent Breast Cancer…
Dec 24, 2024, 14:02 | Science
Stephanie Graff: Abemaciclib Plus Fulvestrant in Advanced Breast Cancer
Stephanie Graff, Director of Breast Oncology at Brown University Health, posted on X about recent…
Dec 13, 2024, 14:02 | Blog
Matthew Kurian: Day 2 at SABCS was one for the books
Matthew Kurian, Assistant Professor of medicine at the University of Kentucky College of Medicine, shared…
Dec 8, 2024, 06:53 | Insight
The role of ADCs in the treatment of patients with Breast Cancer Brain Metastases - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X, about a recent paper by Stacey…
Dec 4, 2024, 09:54 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024
Starting on August 26, in honor of Women’s Equality Day in the United States, which…
Nov 12, 2024, 18:55 | Insight
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Oct 31, 2024, 08:59 | Insight
Self-directed online psychosocial intervention for women with metastatic breast cancer - MASCC
Multinational Association of Supportive Care in Cancer (MASCC) shared a post on X about a recent paper…
Oct 17, 2024, 17:22 | Blog
Brain Penetration Impeded SERD Efficacy in Breast Cancer Pre-Clinical Models
Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute at the Legorreta…
Oct 14, 2024, 11:24 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7
This week, we continue to honor the extraordinary women making waves in the fight against…
Oct 6, 2024, 17:35 | Blog
Sarah Sammons: Demographics of patients with hepatoxicity from ribociclib
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared on X:  "Nice data…
Oct 6, 2024, 16:57 | Blog
Sarah Sammons: Sound advice on how to help a friend with cancer
Sarah Sammons shared a post on X: "I am very lucky to know Renée and she…
Sep 29, 2024, 15:43 | Blog
Paolo Tarantino: The ratio of enrollment to industry-sponsored trials has doubled between 2008-2022
Paolo Tarantino shared the following on X: “Out in JCO: the ratio of enrollment to…
Sep 26, 2024, 16:19 | Blog
Antonio Giordano: Elevating value in cancer care
Antonio Giordano, President of Sbarro Health Research Organization, shared a post on X: ''Elevating value…
Sep 24, 2024, 22:41 | Insight
Paolo Tarantino: What percentage of our patients with ER+/HER2- eBC may qualify for adjuvant CDK4/6i?
Paolo Tarantino shared a post on X: "Now that adjuvant ribociclib is approved, what %…
Sep 20, 2024, 13:00 | Blog
The 1st webinar of the ’24-‘25 EMBRACE Metastatic Breast Cancer Forum Series - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared a post on X: ''Join Nancy Lin, and Sara Tolaney, via Zoom for…
Sep 20, 2024, 06:22 | Blog
Paolo Tarantino: Steroids are the mainstay for treating ADC-induced ILD
Paolo Tarantino shared a post on X by Sarah Sammons adding: "Agree! Steroids are the…
Sep 7, 2024, 10:06 | Blog
Is adjuvant ribociclib ready for prime time?
Sarah Sammons shared a post by Paolo Tarantino, on X: "The number needed to treat (NNT) to…
Sep 4, 2024, 16:11 | Blog
Sarah Sammons: Peter Attia⁩ breaking down ctDNA for CRC screening
Sarah Sammons shared a post on X: ''I have become a fan of ⁦Peter Attia⁩…
Aug 30, 2024, 13:07 | Blog
Sarah Sammons: Breast Cancer Survivor can’t find a PCP for 8 months after calling > 6 places
Sarah Sammons shared on X: “Today I saw a Breast Cancer survivor who moved to…
Aug 27, 2024, 22:07 | Insight
Sarah Sammons: Expanding telehealth is a very important way to overcome disparities in healthcare access
Sarah Sammons shared a post on X: “Expanding telehealth is a very important way to…
Aug 10, 2024, 10:25 | Insight
The critical need to control systemic disease in breast cancer patients who have received stereotactic radiosurgery to brain metastases - Wilmot Cancer Institute
Wilmot Cancer Institute shared on LinkedIn a recent paper by Alex Schick et al. titled…
Jun 12, 2024, 05:36 | Insight
Sarah Sammons: Fatty liver disease in breast cancer survivors
Sarah Sammons shared a post by NEJM on X/Twitter: "We see a decent amount of…
May 13, 2024, 09:09 | Blog
Sarah Sammons: Join us for dinner and lively discussion on novel therapies for HR+ MBC
Sarah Sammons shared on X: "Join Aditya Bardia, Virginia Kaklamani and I 6/1 for dinner…
Apr 30, 2024, 05:53 | Blog
Paolo Tarantino: Grateful to e-join SIOM 2024!
Paolo Tarantino shared a post by Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center…
Apr 28, 2024, 16:53 | Blog
Paolo Tarantino: Unmissable editorial on the current status and next steps for studying and treating brain metastases in breast oncology
Paolo Tarantino shared a post by ESMO Open, on X: "Unmissable editorial on the current status…
Apr 14, 2024, 05:59 | Blog
Sarah Sammons: Sports have so much to teach us and I am here for the rise of women’s basketball
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post by The Sporting…
Apr 7, 2024, 03:41 | Insight
Sarah Sammons: How do we tailor adjuvant therapy without axillary dissection?
Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center, recently shared a post by Massimo…
Mar 28, 2024, 00:47 | Blog
Sarah Sammons: The efficacy of datopotamab deruxtecan in Active BC Brain Metastases
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X: “Paolo…
Mar 16, 2024, 15:39 | Blog
Sarah Sammons: DPYD testing is required before our pharmacy will dispense capecitabine
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post by Vivek Subbiah…
Feb 15, 2024, 18:46 | Blog
Sarah Sammons: Patients with adverse financial events were more likely to have later-stage diagnosis
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter: ''1/3…
Feb 7, 2024, 18:02 | Opinion
Sarah Sammons: Taking actual vacation and having your EMR covered while you are away is linked to reduced burnout
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X: “Taking…
Feb 7, 2024, 14:13 | Blog
Sarah Sammons: When rendering a 2nd opinion that is different from a patients local oncologist, it should be data driven/implementable.
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post on X/Twitter: "To…
Jan 29, 2024, 13:37 | Blog
Sarah Sammons: Learning about Leptomeningeal Disease in Breast Cancer
Sarah Sammons, Breast Medical Oncologist at Dana-Farber's Breast Oncology Center, shared a post on X/Twitter:…
Dec 30, 2023, 17:51 | Opinion
Paolo Tarantino: Happy to have worked with Sarah Sammons and Nancy Lin at the ph2 DATO-Base trial
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared a post…
Dec 12, 2023, 22:33 | Blog
Sarah Sammons: I have always suspected our lobular patients did better with capecitabine!
Sarah Sammons, an oncologist at the Dana-Farber Breast Oncology Center and an Assistant Prof. at the…
Nov 19, 2023, 17:40 | Blog
Sarah Sammons: So wonderful to watch Nancy Lin accept the Massachusetts Clinical Oncology Society Distinguished Clinical Research Award last night
Sarah Sammons, Breast Medical Oncologist at Danna-Farber’s Breast Oncology Centre, shared a post on X/Twitter:…
Nov 17, 2023, 16:48 | Opinion
Sarah Sammons: This is my favorite review ever because it’s honest
Mark Lewis shared an X/Twitter post by Sarah Sammons, an oncologist at the Dana-Farber Breast…
Oct 18, 2023, 17:43 | Stories
Ishwaria Subbiah: We dealt with the issue…without a single email
Some X stories by Mike Feigin, Sarah Sammons and Ishwaria Subbiah. "I have a story…
Oct 15, 2023, 19:08 | Blog
Rebecca Shatsky: It’s not pink and happy, it’s not easy
Rebecca Shatsky recently shared a post by Sarah Sammons on X/Twitter, adding: "This is the…
Sep 10, 2023, 00:15 | Opinion
Sarah Sammons: Expectation and knowledge is power. Surprise is anxiety provoking and perpetually shocking.
Sarah Sammons, Breast Medical Oncologist and Associate Director EMBRACE Metastatic Breast Cancer Program, stated the…
Aug 28, 2023, 18:21 | Opinion
Sarah Sammons: Don’t assume all stage IV cancer patients have “poor prognosis” if it impacts your decisions.
Quoting Sarah Sammons, the Associate Director of EMBRACE Metastatic Breast Cancer Program at Dana-Farber Breast…
Aug 14, 2023, 17:39 | Insight
Check out the new review just published in Cancers MDPI on Tumor Mutational Burden in Breast Cancer - Dana-Farber’s Breast Oncology Center
Quoting from a recent tweet by Dana-Farber’s Breast Oncology Center: "Check out the new review…
Jul 14, 2023, 19:34 | Blog
Hepatotoxicity to Ribociclib is rather common (9% g3/g4) - Dr Sarah Sammons
Hepatotoxicity to Ribociclib is rather common (9% g3/g4). I have had 4 cases now responsive…
All: 66 Posts: 1 - 100
Special Coverage